Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides

Romidepsin belongs to a class of medications called histone deacetylase inhibitors and is currently approved for treatment of cutaneous and peripheral T-cell lymphomas. Romidepsin was previously investigated for the treatment of chronic lymphocytic leukemia (CLL), and demonstrated potential benefit,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemchak, David. M., Akilov, Oleg. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136743/
https://www.ncbi.nlm.nih.gov/pubmed/27994839
http://dx.doi.org/10.4081/hr.2016.6840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136743/
https://www.ncbi.nlm.nih.gov/pubmed/27994839
http://dx.doi.org/10.4081/hr.2016.6840

Ejemplares similares